Biogen (BIIB) 10-Q2017 Q2 Quarterly report

Filed: 25 Jul 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: Abbreviated, acute, Alkem, Amneal, Aurobindo, BENEPALITM, California, cerebral, Cipla, CIRARA, CIRARATM, Circuit, core, counted, counterparty, creation, Delaware, dementia, depicted, disproportionately, DMT, edema, enable, expedite, fatal, feasibility, FLIXABITM, forfeiture, framework, fulminant, FZE, Glenmark, half, hemispheric, Hetero, Impax, IMRALDI, IMRALDITM, infantile, infarction, ischemic, leaner, LHI, liver, Lupin, maximizing, Milan, Ministry, modification, morbidity, mortality, MSN, Mylan, neuroimmunology, neuromuscular, neuropsychiatry, OCREVUSTM, ophthalmology, Par, Pharmathen, preceding, predecessor, Prinston, prioritized, prove, provisionally, Pvt, ransomware, rapidly, reallocate, resilience, SA, Sandoz, Sawai, Shipla, simpler, Slayback, split, Stason, stroke, Sun, surrender, swelling, temporary, Teva, top, Torren, TWI, unclear, unissued, unsuitable, unused, USA, Virginia, Welfare, West, withheld

Removed: aducanumab, advancement, affirming, amiselimod, blood, ceasing, consistent, Crohn, Detail, institute, Italia, neuralgia, North, November, procedure, spin, SRL, trigeminal

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BIIB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: July 25, 2017		/s/ Michel Vounatsos
		Michel Vounatsos
		Chief Executive Officer
		[principal executive officer]



Dated: July 25, 2017		/s/ Gregory F. Covino
		Gregory F. Covino
		Vice President, Finance
		Chief Accounting Officer and
		Interim Principal Financial Officer [principal financial officer]

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.